Oncologic Inc.
This article was originally published in Start Up
Executive Summary
Oncologic Inc. hopes to circumvent the heterogeneity of solid tumors with a multi-step process. It will target two independent cellular cancer characteristics-the presence of an endocytosing receptor, and sensitivity to a chemotherapeutic agent; then erect a novel chemical platform throughout the tumor to hold radioactive isotopes in place to kill the entire tumor, not just individual cancer cells.
You may also be interested in...
CeMines
CeMines has a proprietary method of identifying high volumes of auto-antibody profiles simultaneously; these correlate to regulatory patters in cancer cells, the company believes.
In Vivo's Deals Of The Month, February 2018
In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)
In Vivo's Deals Of The Month, January 2018
In Vivo's editors pick January's most significant deals, including an alliance of players new to health care and Celgene's big buys. (Free article.)